IngredientsGalactomannase is an enzyme that catalyzes the hydrolysis of galactomannans, a type of polysaccharide found in the cell walls of various plants, including guar and locust bean. The term "galactomannase" is a broad, functional name used in the supplement industry and food science literature to describe any enzyme or enzyme complex capable of degrading galactomannan polysaccharides. In the peer-reviewed biochemical literature, this activity is most precisely attributed to two enzyme classes working in concert:
Galactomannans are part of the hemicellulose fraction in lignocellulosic biomass; they are heteropolymers constituted by a β-1,4-linked mannan backbone substituted with side chains of α-1,6-linked galactose residues. Therefore, the joint action of different hydrolytic enzymes — β-mannanase, β-mannosidase, and α-galactosidase — is needed to accomplish their complete hydrolysis.
Efficient bioconversion of galactomannan is performed by the action of glycoside hydrolase (GH), particularly endo-β-1,4-mannanase (EC 3.2.1.78), which catalyzes the random cleavage of β-1,4-mannosidic bonds to produce short mannooligosaccharides (MOS) and mannose. β-Mannanases are categorized into GH families of GH5, 26, 45, 113, and 134 based on the Carbohydrate-Active EnZymes (CAZy) database.
Galactomannans are industrial polysaccharides that are commercially isolated from the seeds of guar, carob, fenugreek, and tara plants. They are heteropolysaccharides composed of D-mannose, which makes up the backbone, and D-galactose, which forms single branches along the mannan chain. They are distinguished from each other based on the mannose-to-galactose ratio (M/G); the ratio ranges approximately between 1:1, 2:1, 3:1 or 4:1 for fenugreek, guar, tara, or locust bean gum, respectively.
Purified galactomannans for industrial usage are obtained from four main plant sources in the sub-family Caesalpinioideae: guar gum from the seeds of Cyamopsis tetragonoloba, locust bean gum from seeds of Ceratonia siliqua (Carob tree), tara gum from seeds of Caesalpinia spinosa, and cassia gum from seeds of Cassia obtusifolia. Fenugreek seeds are rich in galactomannans, containing approximately 25–45% of the polysaccharide by dry weight; fenugreek gum has a mannose-to-galactose ratio of nearly 1:1, giving it excellent water solubility even in cold temperatures.
Galactomannan hydrolysis results from the concerted action of microbial endo-mannanases, mannosidases, and alpha-galactosidases, and is a mechanism of intrinsic biological importance. Enzymes sold as "galactomannase" in the dietary supplement context are typically of microbial origin. The most thoroughly characterized commercial preparation is Hemicell®, for which the active enzyme is endo-1,4-β-D-mannanase. This enzyme is produced by a genetically modified strain of Paenibacillus lentus (formerly named Bacillus lentus). Hemicell™ HT is an exogenous enzyme derived from the fermentation of the Paenibacillus lentus bacteria.
Galactomannase activity is also produced naturally by various fungi (including Trichoderma and Aspergillus species) and aerobic soil bacteria, from which enzyme preparations may be derived for food and supplement use.
In the dietary supplement trade, galactomannase is sold as a component of broad-spectrum digestive enzyme blends, typically in capsule or tablet form, rather than as a standalone product. In such preparations, galactomannase is included specifically to break down galactomannans found in beans and seeds. Enzyme activity in such preparations is commonly expressed in units such as HCU (hemicellulase units) or as IU/mg of preparation. Commercial feed-grade preparations (Hemicell® HT and HT-L) contain a minimum endo-1,4-β-mannanase activity of 1.6 × 108 U/kg (solid) and 5.9 × 108 U/L (liquid), respectively. One β-D-mannanase unit is defined as the amount of enzyme which liberates 1 micromole of reducing sugar equivalent to D-mannose per minute at 50°C and pH 6.0.
Galactomannase activity is also achievable through the enzymatic hydrolysis of guar gum, producing partially hydrolyzed guar gum (PHGG): partially hydrolyzed guar gum (PHGG) is a water-soluble dietary fiber produced through the controlled enzymatic hydrolysis of guar gum.
While the isolated enzyme galactomannase itself has no documented traditional use as a remedy in any historical medical system (it is a product of modern biotechnology), the galactomannan-containing plants that are its natural substrates have long and well-documented histories of use across multiple cultures.
Historically, galactomannan-containing gums have been used for centuries in traditional and industrial food applications as thickening and stabilizing agents. The use of locust bean galactomannan (LBG) in the Mediterranean and the Middle East has been part of traditional food preparation for hundreds of years.
Guar (Cyamopsis tetragonoloba): Guar gum is obtained from the seed of the legume Cyamopsis tetragonolobus. Guar is grown principally as a food crop for animals and an ingredient in human foods; the germ portion of its seed is predominantly protein, and the endosperm is predominantly guar galactomannan. Guar has been cultivated on the Indian subcontinent for centuries as both a food and forage crop.
Fenugreek (Trigonella foenum-graecum): Fenugreek (Trigonella foenum-graecum) is an annual plant belonging to the family Leguminosae or Fabaceae. The seeds of fenugreek contain 26.8% soluble fiber chemically identified as galactomannans with properties similar to soluble fiber of guar seeds and psyllium husk. Fenugreek has been used in Ayurvedic, traditional Egyptian, and Mediterranean medicine for millennia as a digestive aid and metabolic tonic. Beyond its use as a thickener, fenugreek has traditional medicinal uses and is studied for its health benefits.
Carob/Locust Bean (Ceratonia siliqua): Also known as carob gum, locust bean gum (LBG) is derived from the seeds of the carob tree (Ceratonia siliqua), a Mediterranean native. LBG has a higher mannose-to-galactose ratio (about 4:1) compared to guar gum, making it less soluble in cold water but capable of forming strong gels, especially when combined with other hydrocolloids like xanthan gum. Carob pods and seeds have been food staples in Mediterranean countries since antiquity.
The enzyme galactomannase itself emerged as a biotechnological product in the latter half of the 20th century. With the advancement of enzymatic technology, galactomannase has gained attention for its ability to break down these polysaccharides, improving the digestibility and nutritional value of foods, particularly in animal feed and specialized nutritional products for humans.
Galactomannase activity involves sequential hydrolytic steps. The primary enzyme, endo-1,4-β-D-mannanase, carries out internal cleavage of the mannan backbone. Synergism between mannanases and mannosidases appears to be a result of sequential action of the enzymes, where mannanases act on the mannan polymers first, leading to the release of short manno-oligomers, which are the preferred substrates for the mannosidases.
Membrane-bound enzymes from developing legume-seed endosperms catalyze galactomannan biosynthesis in vitro from GDP-mannose and UDP-galactose. A mannosyltransferase (mannan synthase) catalyzes the extension of the linear (1→4)-β-linked D-mannan backbone towards the non-reducing end. A specific α-galactosyltransferase brings about the galactosyl-substitution of the backbone by catalyzing the transfer of a (1→6)-α-D-galactosyl residue to an acceptor mannosyl residue at or close to the non-reducing terminus of the growing backbone. Galactomannase effectively reverses this biosynthetic pattern during digestion.
One of the most important physicochemical effects of galactomannase activity in the gut is a reduction in the viscosity of intestinal contents. Galactomannans are highly viscous polysaccharides when hydrated in the digestive tract, which can impair nutrient absorption by reducing diffusion rates and enzymatic access to food components. Research suggests that supplementation with galactomannase can enhance the breakdown of fiber, potentially improving nutrient absorption and digestive health by reducing the viscosity of intestinal contents. Animal studies confirm this mechanism: in nursery pigs, jejunal digesta viscosity was significantly reduced when β-mannanase was supplemented at 360 U/kg of feed.
A key downstream consequence of galactomannase activity is the production of mannooligosaccharides. Prebiotic mannooligosaccharides (MOS) are small chains of mannose that are known to confer health benefits to the consumers. MOS are also synthesized by the physicochemical or enzymatic treatment of naturally occurring mannans, and these oligomers are being explored for their role in the modulation of beneficial gut microbiota of animals and their possible usage as functional food ingredients in humans.
Separate from their role as substrates for galactomannase, galactomannan polysaccharides have been investigated for their ability to inhibit digestive enzymes involved in glucose metabolism. Research has examined the molecular mechanism of action of galactomannan components on enzyme hydrolysis of glucose polymers using colorimetric assays and 13C HSQC NMR spectroscopy; the starch–iodine colorimetric assay indicated that one galactomannan fraction (GMα) strongly inhibits α-amylase activity. This mechanism is associated with the intact, undigested galactomannan — not with the enzyme galactomannase itself.
It is important to note that human studies showed that the physiologic effects of guar gum were not decreased after treatment with galactomannase, an enzyme that could degrade the mannose and galactose units. This finding suggests that at least some health-relevant properties of galactomannans are retained even after partial enzymatic degradation.
Animal and in vitro evidence (substantial): The evidence base for galactomannase's effects on digestion is most extensive in animal nutrition, where multiple controlled trials have been conducted.
In nursery pigs, β-mannanase supplementation linearly reduced TNF-α, IgG, MDA, and protein carbonyl in the duodenum, and TNF-α, IgG, and MDA in the jejunum. Additionally, β-mannanase supplementation linearly increased villus height to crypt depth ratio and crypt cell proliferation in the jejunum.
In broiler studies, β-mannanase increased total tract retention of dry matter, nitrogen, soluble non-starch polysaccharides, insoluble NSP, total NSP, free oligosaccharides, and calcium, and showed a tendency to increase nitrogen-corrected apparent metabolizable energy. During the early growth phase, birds offered diets supplemented with β-mannanase had higher weight gain, and β-mannanase supplementation improved feed conversion ratio (FCR).
In animal nutrition, several trials have demonstrated improved feed efficiency and growth performance in poultry and livestock when galactomannase is included in diets high in galactomannans. While there is growing interest in its use for human nutrition, especially for individuals with digestive challenges, large-scale clinical trials in humans remain limited.
Human evidence (preliminary/weak): Preliminary research indicates potential benefits such as supporting gut health and aiding in the management of certain gastrointestinal conditions. However, more rigorous clinical data are necessary to fully establish its efficacy in human populations. No large, placebo-controlled, randomized human trials specifically testing galactomannase as a supplement ingredient for digestive health outcomes (as distinct from its galactomannan substrate) were identified in peer-reviewed sources at the time of this writing.
Evidence for glycemic effects relates primarily to the unhydrolyzed galactomannan substrates (notably guar gum), with some evidence touching on the role of the enzyme in modifying those effects.
Human clinical trial evidence (moderate to strong for galactomannan substrate): A 2023 GRADE-assessed systematic review and meta-analysis of 14 RCTs found that guar gum supplementation led to significant reductions in hemoglobin A1c (HbA1c) (WMD: −0.47 mg/dL, 95% CI: −0.75, −0.18, p = 0.001); there was no effect on fasting blood sugar, systolic and diastolic blood pressure, or body mass in comparison with the control group overall. A subgroup analysis demonstrated that intervention in patients with type 2 diabetes (T2DM), and high supplementation dosages (>15 g/d), significantly decreased fasting blood sugar concentrations.
A randomized, double-blind, crossover study in 25 healthy nonobese middle-aged men given 10 grams of guar or placebo granulate three times a day for 6 weeks demonstrated decreases in fasting blood glucose, cholesterol, triglycerides, plasminogen activator inhibitor-1 activity, systolic blood pressure, and diastolic blood pressure during guar treatment when compared with placebo. Insulin sensitivity, measured with the euglycemic-clamp technique, also increased.
A randomized, double-blind, crossover study in patients with insulin-dependent diabetes found that fasting blood glucose and hemoglobin A1c decreased significantly during the guar-gum diet; in addition, serum LDL cholesterol decreased by 20% and the ratio of LDL cholesterol to high-density-lipoprotein cholesterol by 28% during guar-gum therapy.
A network meta-analysis published in the American Journal of Clinical Nutrition concluded that galactomannans could significantly reduce HbA1c and fasting blood glucose levels; they could also decrease triglycerides and LDL levels.
Important caveat: These glycemic benefits were studied using intact galactomannans (primarily guar gum). The role of the enzyme galactomannase in this context is related to producing hydrolyzed forms; notably, human studies showed that the physiologic effects of guar gum were not decreased after treatment with galactomannase, an enzyme that could degrade the mannose and galactose units.
Human clinical evidence (moderate for galactomannan substrate): An early double-blind, crossover trial in 14 male subjects with hypercholesterolemia found that participants received daily supplementation with granulated guar gum or placebo, 15 g/day, during 12 weeks. A statistically significant reduction in serum total cholesterol (7.27 ± 0.24 vs. 8.23 ± 0.26 mmol/L, p < 0.01), mainly due to a reduction in LDL cholesterol, was observed after 6 weeks on guar gum compared with placebo. Between 6 and 12 weeks, serum cholesterol and LDL cholesterol levels increased in most subjects, and after 12 weeks the difference from placebo was no longer statistically significant.
Recent meta-analytic work indicated that guar gum supplementation might improve lipid profile markers in different populations. However, critical methodological limitations, such as the use of some unreliable data and the lack of inclusion of several relevant studies, and the scarcity of assessments of regression and dose-specific effects, make it difficult to draw meaningful conclusions. Current evidence regarding the effects of guar gum supplementation on lipid profile remains unclear.
Well-controlled intervention studies have shown that four major water-soluble fiber types — β-glucan, psyllium, pectin, and guar gum — effectively lower serum LDL cholesterol concentrations. The mechanism is believed to relate to the viscosity of the intact polysaccharide in the gut lumen, affecting bile acid reabsorption.
Evidence (in vitro and animal; limited human data): Enzymatic hydrolysis of galactomannans by galactomannase generates mannooligosaccharides (MOS), which have been investigated for prebiotic activity. These oligomers are being explored for their role in the modulation of beneficial gut microbiota of animals, and experimental evidence strongly indicates that dietary MOS impart numerous health benefits, including antineoplastic, immunomodulatory, and hypolipidemic effects, indicating that they have immense potential as a functional food ingredient.
Galactomannan is known to be fermented in the human gut. A deeper understanding of the utilization of different dietary fibers by gut microbes and the mechanisms involved will likely expand possibilities to affect our microfloral balance through diet.
Some prebiotic fibers, such as mannan-oligosaccharides (MOS), may be a promising alternative therapy in gut health contexts. In addition to selectively growing commensal bacteria and creating a diverse gut microbiota, MOS have a high affinity for specific binding arms on the structure of some pathogenic bacteria. This potential to competitively bind pathogens has been proposed as an additional mechanism of benefit.
Clinical trials have demonstrated that guar gum, a rich source of galactomannan, improves symptoms in irritable bowel syndrome (IBS) and chronic constipation. Additionally, galactomannan's prebiotic effects may contribute to a healthier gut microbiota composition. The magnitude of its benefits for general intestinal health is moderate, and some individuals may experience gastrointestinal discomfort such as bloating or gas, especially when intake is suddenly increased. There is moderate scientific evidence supporting the use of galactomannan as a fiber supplement to promote intestinal health and regularity, mainly due to its mechanical effects as a soluble fiber and its prebiotic potential, but there is less evidence for its use in treating specific gastrointestinal diseases.
Evidence (animal only; no direct human data for galactomannase supplementation): In nursery pig studies, β-mannanase supplementation linearly reduced pro-inflammatory markers including TNF-α, IgG, malondialdehyde (MDA), and protein carbonyl in the duodenum. In grower pigs, those fed diets with the highest level of metabolizable energy reduction supported by β-mannanase had lower serum IL-1β concentration. These findings indicate possible anti-inflammatory downstream effects mediated by reduced luminal viscosity and improved intestinal morphology, but translation to humans has not been established in clinical trials.
Mannooligosaccharides are being explored for their role in the modulation of beneficial gut microbiota of animals and their possible usage as functional food ingredients in humans. Experimental evidence strongly indicates that dietary MOS impart numerous health benefits, including antineoplastic, immunomodulatory, and hypolipidemic effects. However, most of these findings remain at the preclinical stage.
Based on the available peer-reviewed evidence, galactomannase and/or its galactomannan substrates are associated with the following body systems and health areas:
No standardized human dosage for galactomannase as an isolated supplement has been established in clinical trials. In animal nutrition research, dosages studied include:
Where galactomannase enzymes are used to modify galactomannans for human ingestion, the dosages used in human clinical trials relate to the galactomannan substrate:
Regarding the form of galactomannan used: an important benefit of using depolymerized guar gum (i.e., galactomannase-treated) is that much larger quantities of the galactomannan can be incorporated into food products without serious loss of sensory qualities.
The enzyme galactomannase (as endo-1,4-β-D-mannanase) has been most extensively evaluated by the European Food Safety Authority (EFSA) in the context of animal feed additives. The additive Hemicell®-L is a liquid preparation of endo-1,4-β-mannanase that is authorized as a zootechnical feed additive for chickens for fattening. The applicant requested the renewal of the authorization, new uses, and modification of the manufacturing process. The new production strain is a genetically modified strain of Paenibacillus lentus obtained from a strain previously evaluated by EFSA and considered to be safe; the EFSA FEEDAP Panel evaluated the genetic modification and concluded that the sequences introduced to obtain the production strain did not raise safety concerns.
The additive is safe for the target species at the corresponding recommended doses. The use of Hemicell® HT as a feed additive does not give rise to concerns for consumers. Hemicell® HT and Hemicell® HT-L are not irritant to the skin and eyes; however, Hemicell® HT (the solid form) is a skin sensitizer.
Hemicell® HT/HT-L produced by Paenibacillus lentus DSM 33618 is considered safe for target species at the intended conditions of use. The use of this preparation as a feed additive raises no concerns for the consumer or for the environment.
Hemicell® HT (the dry, solid enzyme preparation) is a skin sensitizer, which is a known occupational concern for individuals handling bulk enzyme powders in manufacturing or feed-mixing environments. This is a standard class concern for enzyme powders and does not apply to consumers taking encapsulated dietary supplements.
Some individuals may experience gastrointestinal discomfort, such as bloating or gas, especially when intake of galactomannans is suddenly increased. This applies primarily to the galactomannan substrate rather than to the enzyme itself, and is consistent with the known effects of rapidly increasing dietary fiber intake.
A pharmacologically relevant safety/efficacy interaction note is that human studies showed that the physiologic effects of guar gum were not decreased after treatment with galactomannase, an enzyme that could degrade the mannose and galactose units. This indicates that even enzymatically modified (hydrolyzed) galactomannans retain their glucose-modulating activity, which is relevant for patients taking medications for diabetes or blood sugar management.
No peer-reviewed human clinical evidence characterizing pharmacokinetic or pharmacodynamic interactions between supplemental galactomannase and any specific drug class was identified in the literature reviewed. Given the glycemic-lowering properties of galactomannan substrates demonstrated in RCTs (see Section 4.2), patients on antidiabetic agents who consume large amounts of galactomannan-rich fiber alongside galactomannase preparations may warrant monitoring of blood glucose levels, though this interaction has not been directly studied for the enzyme supplement specifically.
Health conditions that Galactomannase may help support.
Body systems that Galactomannase may help support.
Go back